These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915 [TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
4. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
5. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. Miyoshi T; Nakamura K; Doi M; Ito H Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669 [TBL] [Abstract][Full Text] [Related]
6. [PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?]. Parhofer KG Herz; 2016 May; 41(3):217-23. PubMed ID: 26961236 [TBL] [Abstract][Full Text] [Related]
7. Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Penno G; Solini A; Zoppini G; Fondelli C; Trevisan R; Vedovato M; Gruden G; Lamacchia O; Pontiroli AE; Arosio M; Orsi E; Pugliese G; PLoS One; 2015; 10(5):e0125512. PubMed ID: 25942403 [TBL] [Abstract][Full Text] [Related]
8. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. Hu D; Yang Y; Peng DQ Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466 [TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
10. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study. Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724 [TBL] [Abstract][Full Text] [Related]
11. PCSK9 and its modulation. Cui CJ; Li S; Li JJ Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750 [TBL] [Abstract][Full Text] [Related]
12. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
13. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Konarzewski M; Szolkiewicz M; Sucajtys-Szulc E; Blaszak J; Lizakowski S; Swierczynski J; Rutkowski B Am J Nephrol; 2014; 40(2):157-63. PubMed ID: 25171595 [TBL] [Abstract][Full Text] [Related]
14. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
15. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202 [TBL] [Abstract][Full Text] [Related]
16. PCSK9 in chronic kidney disease. Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558 [TBL] [Abstract][Full Text] [Related]
17. Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population. Zhang HW; Zhao X; Xu RX; Guo YL; Zhu CG; Wu NQ; Cui CJ; Dong Q; Li JJ Cardiorenal Med; 2018; 8(4):311-320. PubMed ID: 30121647 [TBL] [Abstract][Full Text] [Related]